Last reviewed · How we verify

Oral antihyperglycemics

Eli Lilly and Company · Phase 3 active Small molecule

Oral antihyperglycemics is a Oral antihyperglycemic agents (multiple classes) Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 3 development for Type 2 diabetes mellitus.

Oral antihyperglycemics lower blood glucose levels through various mechanisms including insulin secretion enhancement, insulin sensitivity improvement, or glucose absorption reduction.

Oral antihyperglycemics lower blood glucose levels through various mechanisms including insulin secretion enhancement, insulin sensitivity improvement, or glucose absorption reduction. Used for Type 2 diabetes mellitus.

At a glance

Generic nameOral antihyperglycemics
SponsorEli Lilly and Company
Drug classOral antihyperglycemic agents (multiple classes)
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

This is a broad drug class rather than a single agent, encompassing multiple mechanistic approaches to glycemic control. Eli Lilly's oral antihyperglycemic portfolio includes agents such as sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, and SGLT2 inhibitors, each targeting different pathways in glucose homeostasis. The specific mechanism depends on the individual compound within the class.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Oral antihyperglycemics

What is Oral antihyperglycemics?

Oral antihyperglycemics is a Oral antihyperglycemic agents (multiple classes) drug developed by Eli Lilly and Company, indicated for Type 2 diabetes mellitus.

How does Oral antihyperglycemics work?

Oral antihyperglycemics lower blood glucose levels through various mechanisms including insulin secretion enhancement, insulin sensitivity improvement, or glucose absorption reduction.

What is Oral antihyperglycemics used for?

Oral antihyperglycemics is indicated for Type 2 diabetes mellitus.

Who makes Oral antihyperglycemics?

Oral antihyperglycemics is developed by Eli Lilly and Company (see full Eli Lilly and Company pipeline at /company/eli-lilly).

What drug class is Oral antihyperglycemics in?

Oral antihyperglycemics belongs to the Oral antihyperglycemic agents (multiple classes) class. See all Oral antihyperglycemic agents (multiple classes) drugs at /class/oral-antihyperglycemic-agents-multiple-classes.

What development phase is Oral antihyperglycemics in?

Oral antihyperglycemics is in Phase 3.

What are the side effects of Oral antihyperglycemics?

Common side effects of Oral antihyperglycemics include Hypoglycemia, Gastrointestinal disturbances, Weight gain, Lactic acidosis (biguanides).

Related